S&P 500   3,844.54 (-1.44%)
DOW   30,877.27 (-1.20%)
QQQ   281.69 (-2.72%)
AAPL   134.29 (-2.23%)
MSFT   247.07 (-2.40%)
FB   190.19 (-0.58%)
GOOGL   2,129.76 (-3.53%)
AMZN   2,114.00 (-1.51%)
TSLA   641.17 (-9.62%)
NVDA   160.30 (-6.39%)
BABA   85.71 (-2.26%)
NIO   16.02 (-3.84%)
AMD   89.72 (-7.19%)
CGC   5.39 (-8.18%)
MU   66.73 (-3.85%)
T   20.22 (+0.05%)
GE   74.24 (-1.98%)
F   12.31 (-4.20%)
DIS   100.71 (-2.36%)
AMC   11.59 (-11.39%)
PFE   51.85 (+2.37%)
PYPL   78.28 (-3.69%)
NFLX   181.51 (-1.07%)
S&P 500   3,844.54 (-1.44%)
DOW   30,877.27 (-1.20%)
QQQ   281.69 (-2.72%)
AAPL   134.29 (-2.23%)
MSFT   247.07 (-2.40%)
FB   190.19 (-0.58%)
GOOGL   2,129.76 (-3.53%)
AMZN   2,114.00 (-1.51%)
TSLA   641.17 (-9.62%)
NVDA   160.30 (-6.39%)
BABA   85.71 (-2.26%)
NIO   16.02 (-3.84%)
AMD   89.72 (-7.19%)
CGC   5.39 (-8.18%)
MU   66.73 (-3.85%)
T   20.22 (+0.05%)
GE   74.24 (-1.98%)
F   12.31 (-4.20%)
DIS   100.71 (-2.36%)
AMC   11.59 (-11.39%)
PFE   51.85 (+2.37%)
PYPL   78.28 (-3.69%)
NFLX   181.51 (-1.07%)
S&P 500   3,844.54 (-1.44%)
DOW   30,877.27 (-1.20%)
QQQ   281.69 (-2.72%)
AAPL   134.29 (-2.23%)
MSFT   247.07 (-2.40%)
FB   190.19 (-0.58%)
GOOGL   2,129.76 (-3.53%)
AMZN   2,114.00 (-1.51%)
TSLA   641.17 (-9.62%)
NVDA   160.30 (-6.39%)
BABA   85.71 (-2.26%)
NIO   16.02 (-3.84%)
AMD   89.72 (-7.19%)
CGC   5.39 (-8.18%)
MU   66.73 (-3.85%)
T   20.22 (+0.05%)
GE   74.24 (-1.98%)
F   12.31 (-4.20%)
DIS   100.71 (-2.36%)
AMC   11.59 (-11.39%)
PFE   51.85 (+2.37%)
PYPL   78.28 (-3.69%)
NFLX   181.51 (-1.07%)
S&P 500   3,844.54 (-1.44%)
DOW   30,877.27 (-1.20%)
QQQ   281.69 (-2.72%)
AAPL   134.29 (-2.23%)
MSFT   247.07 (-2.40%)
FB   190.19 (-0.58%)
GOOGL   2,129.76 (-3.53%)
AMZN   2,114.00 (-1.51%)
TSLA   641.17 (-9.62%)
NVDA   160.30 (-6.39%)
BABA   85.71 (-2.26%)
NIO   16.02 (-3.84%)
AMD   89.72 (-7.19%)
CGC   5.39 (-8.18%)
MU   66.73 (-3.85%)
T   20.22 (+0.05%)
GE   74.24 (-1.98%)
F   12.31 (-4.20%)
DIS   100.71 (-2.36%)
AMC   11.59 (-11.39%)
PFE   51.85 (+2.37%)
PYPL   78.28 (-3.69%)
NFLX   181.51 (-1.07%)
NASDAQ:VCEL

Vericel (VCEL) Stock Forecast, Price & News

$27.01
-0.78 (-2.81%)
(As of 05/20/2022 03:15 PM ET)
Add
Compare
Today's Range
$26.68
$28.38
50-Day Range
$25.43
$39.58
52-Week Range
$25.11
$68.94
Volume
5,135 shs
Average Volume
568,580 shs
Market Capitalization
$1.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.96
30 days | 90 days | 365 days | Advanced Chart
Receive VCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

Vericel logo

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Headlines

Vericel (VCEL) Q1 2022 Earnings Call Transcript
Vericel: Poised For Growth - Seeking Alpha
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCEL
Employees
281
Year Founded
1989

Sales & Book Value

Annual Sales
$156.18 million
Book Value
$3.66 per share

Profitability

Net Income
$-7.47 million
Pretax Margin
-7.31%

Debt

Price-To-Earnings

Miscellaneous

Free Float
44,670,000
Market Cap
$1.27 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/20/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

805th out of 1,420 stocks

Biological Products, Except Diagnostic Industry

128th out of 209 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













Vericel (NASDAQ:VCEL) Frequently Asked Questions

Is Vericel a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vericel stock.
View analyst ratings for Vericel
or view top-rated stocks.

When is Vericel's next earnings date?

Vericel is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Vericel
.

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) posted its quarterly earnings data on Wednesday, May, 4th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.03. The biotechnology company earned $36.07 million during the quarter, compared to analyst estimates of $34.31 million. Vericel had a negative trailing twelve-month return on equity of 6.93% and a negative net margin of 7.15%. The firm's revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.07) earnings per share.
View Vericel's earnings history
.

What guidance has Vericel issued on next quarter's earnings?

Vericel updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $178.00 million-$189.00 million, compared to the consensus revenue estimate of $183.55 million.

What price target have analysts set for VCEL?

3 brokerages have issued 12 month price objectives for Vericel's shares. Their forecasts range from $45.00 to $52.00. On average, they expect Vericel's stock price to reach $48.50 in the next year. This suggests a possible upside of 80.7% from the stock's current price.
View analysts' price targets for Vericel
or view top-rated stocks among Wall Street analysts.

Who are Vericel's key executives?
Vericel's management team includes the following people:
  • Mr. Dominick C. Colangelo Esq., CEO, Pres & Director (Age 58, Pay $1.36M)
  • Mr. Joseph Anthony Mara Jr., CFO & Treasurer (Age 46, Pay $636.24k)
  • Mr. Michael Halpin, Chief Operating Officer (Age 61, Pay $672.86k) (LinkedIn Profile)
  • Mr. Sean C. Flynn, Sr. VP, Gen. Counsel & Sec. (Age 48, Pay $556.66k) (LinkedIn Profile)
  • Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B., Chief Medical Officer (Age 60, Pay $578.36k)
  • Mr. Jonathan Siegal, Principal Accounting Officer, VP & Corp. Controller
  • Mr. Eric Burns, Exec. Director of Financial Planning and Analysis & Investor Relations
  • Mr. Patrick J. Fowler, Sr. VP of Corp. Devel. & Strategy
  • Ms. Heidi Hassen, VP of HR
  • Mr. Roland DeAngelis, Sr. VP of Commercial Operations
What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel CEO Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among Vericel's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Who are Vericel's major shareholders?

Vericel's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.08%), RTW Investments LP (8.53%), Vanguard Group Inc. (6.38%), State Street Corp (6.24%), Conestoga Capital Advisors LLC (5.53%) and Federated Hermes Inc. (3.45%). Company insiders that own Vericel stock include Dominick Colangelo, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends for Vericel
.

Which major investors are selling Vericel stock?

VCEL stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Federated Hermes Inc., Invesco Ltd., UBS Group AG, Citigroup Inc., JPMorgan Chase & Co., Vanguard Group Inc., and PDT Partners LLC. Company insiders that have sold Vericel company stock in the last year include Jonathan Mark Hopper, Michael Halpin, Sean C Flynn, and Steven C Gilman.
View insider buying and selling activity for Vericel
or view top insider-selling stocks.

Which major investors are buying Vericel stock?

VCEL stock was acquired by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, GW&K Investment Management LLC, Fort Washington Investment Advisors Inc. OH, Lisanti Capital Growth LLC, State Street Corp, Royal Bank of Canada, Comerica Bank, and New York State Common Retirement Fund.
View insider buying and selling activity for Vericel
or or view top insider-buying stocks.

How do I buy shares of Vericel?

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $26.84.

How much money does Vericel make?

Vericel has a market capitalization of $1.26 billion and generates $156.18 million in revenue each year. The biotechnology company earns $-7.47 million in net income (profit) each year or ($0.25) on an earnings per share basis.

How many employees does Vericel have?

Vericel employs 281 workers across the globe.

When was Vericel founded?

Vericel was founded in 1989.

What is Vericel's official website?

The official website for Vericel is www.vcel.com.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (800) 556-0311, via email at [email protected], or via fax at 617-588-5554.

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.